Azienda Ospedaliera Papardo — Clinical Trial Site

28 Registered trials

8 Currently recruiting

Organisation

Azienda Ospedaliera Papardo

Location

Messina, Italy

Identifier

ORG-100048747

Address

Viale Ferdinando Stagno D'Alcontres Contrada Papardo, 98158, Italy

Departments

#1709: Unità Operativa Oncologia Medica
01-037:UOC Ematologia
03915:Medical Oncology Unit
4102: U.O.Oncologia Medica, Medical Oncology Unit
Ematologia
Hematology
Medical oncology
Medical Oncology Department
Onco-hematology department
Oncologia Medica
oncology
S.C. Ematologia
SC EMATOLOGIA
U.O.C. Oncologia Medica
UOC Oncologia medica
UOC Oncologia medica 1

Clinical trials at this site (28)

Search interface

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending

2024-514701-57-01 non Small Cell Lung Cancer 4
Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari… Pending

2025-521651-22-00 hormone receptor positive, HER2-negative breast cancer 4
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting

2023-505775-70-00 High risk smoldering multiple myeloma 4 2024-04-08
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting

2023-510431-11-00 Chronic Lymphocytic Leukemia 4 2023-07-21
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Brain Metastasis from Estrogen Receptor Positive, HER-2 9 2023-05-16
phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate… Recruiting

2024-511631-10-00 Hodgkin’s lymphoma 9 2023-02-27
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COM… Recruiting

2024-516330-35-00 Non-Small Cell Lung Cancer 5 2021-09-29
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting

2024-513372-18-00 Pre- and post-menopausal women with HR+/HER2- LABC or M 4 2019-10-18
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Follicular Lymphoma 5 2021-12-01
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended

2023-507697-40-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-07-05
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended

2024-516653-44-00 HER2-Low, Hormone Receptor Positive Breast Cancer which 5 2020-11-30
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g… Ended

2023-504974-40-00 Estrogen Receptor Positive HER2 Negative Advanced Breas 4 2020-04-24
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended

2024-511641-18-00 Diffuse Large B-cell Lymphoma ABC 4 2019-08-01
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended

2024-513396-41-00 PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE > 5 2019-05-15
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended

2024-512049-17-00 Newly diagnosed MM patients >= 65 years old or ineligib 6 2018-09-05
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) 6 2016-10-17